InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,076.00
(
0.00%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
84.00
(
0.44%
)
Bitcoin
59,396.21
(
0.47%
)
Post# of 251692
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 204452

Friday, 09/22/2017 10:49:54 AM

Friday, September 22, 2017 10:49:54 AM

Post# of 251692
AGN reports mixed phase-2b NASH data:

https://finance.yahoo.com/news/data-centaur-phase-2b-clinical-120000624.html

In the patients who remained on treatment for two years, there was no significant difference between CVC and placebo in the composite endpoint – reduction in fibrosis by at least one stage with no worsening of NASH. However, in patients with higher baseline fibrosis scores, patients who received CVC had better outcomes during the two year treatment period.

CVC is the drug AGN obtained in the controversial buyout of Tobira (#msg-125266132).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up